Year 2022 (56)

Edition nr. 12

Interchangeability of biosimilars

Over the last 15 years, a large number of so-called ‘biosimilars’ have been marketed. Biosimilars are biological drugs that have been copied from the biological reference drug after the period of market protection had ended. They are comparable t ...

In short Read article

New drug: lasmiditan for migraine attacks

Two new drugs for the acute treatment of migraine attacks were authorised in 2022. They concern the ‘calcitonin gene-related peptide’ (CGRP) antagonist rimegepant, which was previously discussed in Ge-Bu, and the 5HT1F agonist lasmiditan. New age ...

In short Read article